See What HealthDay Can Do For You
Contact Us

Chloroquine COVID-19 Trial Stopped After Patient Deaths

Some patients taking a higher dose developed serious heart rhythm disorders, resulting in 11 deaths

pills

MONDAY, April 13, 2020 (HealthDay News) -- A study of chloroquine in coronavirus 2019 (COVID-19) patients was halted due to potentially deadly side effects.

Researchers in Brazil were testing chloroquine in 81 hospitalized COVID-19 patients. About half were prescribed 450 mg twice daily for five days, and the others were prescribed 600 mg for 10 days, The New York Times reported. But within three days, some patients taking the higher dose developed serious heart rhythm disorders, resulting in 11 deaths. The researchers immediately stopped the higher-dose part of the trial. The trial did not have enough patients in the lower-dose trial to conclude whether chloroquine was effective in patients with severe cases of COVID-19.

"To me, this study conveys one useful piece of information, which is that chloroquine causes a dose-dependent increase in an abnormality in the electrocardiogram that could predispose people to sudden cardiac death," David Juurlink, M.D., an internist and the head of the division of clinical pharmacology at the University of Toronto, told The Times.

Patients in the trial also received the antibiotic azithromycin, which also has heart rhythm disorder risks. Hospitals in the United States are using azithromycin to treat COVID-19 patients, often in combination with hydroxychloroquine, according to The Times.

The New York Times Article

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.